Quantum Pharmaceutical appoints commercial director

Victoria Buyer has 10 years of industry experience

Quantum Pharmaceutical, a UK-based pharmaceutical specials manufacturer, has appointed Victoria Buyer as commercial director.

With a decade’s industry experience, Buyer has previously been responsible for the growth and development of companies including GlaxoSmithKline and Alliance UniChem.

Buyer said: ‘Quantum already strives to ensure its operations are at the forefront of the marketplace – and I’m determined to build on its strong foundations and forge links with new partners while reinforcing collaboration with our loyal customer network.’

You may also like

Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
Manufacturing

Asymchem fully automates its therapeutic peptide manufacturing processes

The company has facilitated the scale-up of its peptide manufacturing capabilities, with its production capacity now standing at 10,000 L
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Manufacturing

How AI can optimise your pharmaceutical manufacturing processes and raise throughput

Artificial intelligence (AI) allows pharmaceutical manufacturers to perform predictive maintenance, which can reduce downtime and enhance process efficiency
Manufacturing

IMed supports K2 medical systems in their EU MDR transition

Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
Manufacturing

Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger

Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
Subscribe now